|
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
Jul 31, 2026 Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation Jul 30, 2026 Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD) Jul 30, 2026 Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? Jul 30, 2026 Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial Jul 30, 2026 Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL Jul 29, 2026 Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial Jul 29, 2026 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Jul 29, 2026 Rethinking Regulatory Protections for Accelerated Approvals With Supplementary Indications Jul 29, 2026 He Was Always There Jul 28, 2026 Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial Jul 27, 2026 SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer Jul 27, 2026 Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer Jul 27, 2026 Time-Varying Effects of Copy Number Alteration Clustering: Methodologic Concerns in Survival Analysis of Relapsed/Refractory Germ Cell Tumors Jul 27, 2026 Anti-TIGIT in PD-L1–High Advanced Non–Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward Jul 27, 2026 Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801) Jul 27, 2026 |
Purple Blossoms Journal of Clinical Oncology, Volume 44, Issue 30, Page 2972-2974, October 2026. <br/> 2026-10-20T07:00:00Z Bridging the Gap: Precision Oncology for Cancers of Unknown Primary Journal of Clinical Oncology, Volume 44, Issue 30, Page 2886-2890, October 2026. <br/> 2026-10-20T07:00:00Z Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial Journal of Clinical Oncology, Volume 44, Issue 30, Page 2929-2940, October 2026. <br/> 2026-10-20T07:00:00Z Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer Journal of Clinical Oncology, Volume 44, Issue 30, Page 2903-2907, October 2026. <br/> 2026-10-20T07:00:00Z Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial Journal of Clinical Oncology, Volume 44, Issue 30, Page 2941-2952, October 2026. <br/> 2026-10-20T07:00:00Z Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study Journal of Clinical Oncology, Volume 44, Issue 30, Page 2895-2902, October 2026. <br/> 2026-10-20T07:00:00Z Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update Journal of Clinical Oncology, Volume 44, Issue 30, Page 2953-2971, October 2026. <br/> 2026-10-20T07:00:00Z Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR Journal of Clinical Oncology, Volume 44, Issue 30, Page 2919-2928, October 2026. <br/> 2026-10-20T07:00:00Z Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial Journal of Clinical Oncology, Volume 44, Issue 30, Page 2908-2918, October 2026. <br/> 2026-10-20T07:00:00Z Should We Call Every Cancer a Rare Cancer? Journal of Clinical Oncology, Volume 44, Issue 30, Page 2891-2894, October 2026. <br/> 2026-10-20T07:00:00Z Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope? Journal of Clinical Oncology, Volume 44, Issue 30, Page 2976-2977, October 2026. <br/> 2026-10-20T07:00:00Z Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer? Journal of Clinical Oncology, Volume 44, Issue 30, Page 2975-2976, October 2026. <br/> 2026-10-20T07:00:00Z Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression Journal of Clinical Oncology, Volume 44, Issue 30, Page 2979-2979, October 2026. <br/> 2026-10-20T07:00:00Z Erratum: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Journal of Clinical Oncology, Volume 44, Issue 30, Page 2979-2979, October 2026. <br/> 2026-10-20T07:00:00Z Erratum: Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study Journal of Clinical Oncology, Volume 44, Issue 30, Page 2980-2980, October 2026. <br/> 2026-10-20T07:00:00Z Reply to: “Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?” and “Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?” Journal of Clinical Oncology, Volume 44, Issue 30, Page 2977-2978, October 2026. <br/> 2026-10-20T07:00:00Z |
Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL
In a trial involving adults with Ph-positive acute lymphoblastic leukemia, 24-month event-free survival was 86% with the TKI–immunotherapy combination ponatinib–blinatumomab and 67% with imatinib plus chemotherapy. 2026-10-15
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema In a phase 3, randomized trial of lonvo-z, an in vivo gene-editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. 2026-10-15
Case 29-2026: A 39-Year-Old Man with Abdominal Pain, Foot Drop, and a Spinal Mass A 39-year-old man, who was an Iraq War veteran with exposure to burn pits, was admitted to the hospital with hypertension, abdominal pain, and foot drop. Imaging showed a thoracic spinal mass. A diagnosis was made. 2026-10-15
Flushing in Carcinoid Syndrome A 44-year-old man was admitted for the management of carcinoid syndrome, which had been diagnosed 4 years earlier. On examination, mottled, violaceous, blanchable flushing was seen across the face and torso. 2026-10-15
Adapting to Genomic Medicine Hereditary angioedema is a disorder characterized by unpredictable, transient episodes of swelling and pain of various body parts. It can be life-threatening if the airway is involved. Current therapies include several different products that are administered prophylactically or at the onset of symptoms, and the prophylactic products must be administered... 2026-10-15
IARC Perspective on Lung Cancer Screening The 21st volume of the IARC Handbooks summarizes and evaluates evidence for the benefits and harms of lung cancer screening with low-dose CT or chest radiography and assesses tools and strategies to improve screening. 2026-10-15
Chemotherapy-free Treatment of Ph-Positive ALL It would be rare for anyone who has undergone intensive, multicycle, multiagent chemotherapy followed by allogeneic hematopoietic stem-cell transplantation to agree with Nietzsche’s personal view that “Out of life’s school of war, what does not kill me, makes me stronger.” Even though our past approaches to treating patients with the... 2026-10-15
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. 2026-10-08
Advances in Systemic Treatment of Breast Cancer This review summarizes advances in therapy, including approval or expanded use of targeted agents, improved outcomes with antibody–drug conjugates and immunotherapy, and growing reliance on molecular profiling. 2026-10-08
Case 28-2026: A 19-Year-Old Woman with Fever, Cervical Lymphadenopathy, and Leukopenia A 19-year-old woman presented with fever and cervical lymphadenopathy. The white-cell count was 2900 per microliter (reference range, 4000 to 11,000), and the lactate dehydrogenase level was elevated. A diagnosis was made. 2026-10-08
A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer The diagnosis of cancer at earlier stages is generally associated with improved survival. Detecting circulating tumor–derived cell-free DNA (cfDNA) is an established method of monitoring the response to therapy for many cancer types, particularly hematopoietic and metastatic cancers — which leads to the question of whether screening for cfDNA in... 2026-10-08
Giredestrant plus Everolimus in Advanced Breast Cancer In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. 2026-10-01
Joint Clinical Assessments — A New Chapter in European Pharmaceutical Policy A new European Union regulation introduces a centralized clinical assessment process for comparing the effectiveness and safety of new medicines with those of the standards of care in various countries. 2026-10-01
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. 2026-09-24
Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome Persons with Wiskott–Aldrich syndrome were treated with an autologous gene therapy consisting of hematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding WAS complementary DNA. 2026-09-24
Clinical Uses of Common Genetic Variants Associated with Common Diseases The authors review the ways common genetic variants, polygenic risk scores, and pharmacogenomic genotyping may be useful in the prevention of common diseases and the treatment of common diseases after diagnosis. 2026-09-24
Science behind the Study: Anito-cel for Multiple Myeloma The author describes the science behind a phase 1 study of anitocabtagene autoleucel, a CAR T cell that deploys a CAR with a novel synthetic antigen-binding domain, in patients with multiple myeloma. 2026-09-24
A Cure Out of Most Patients’ Reach — Sickle Cell Disease in the Gene-Therapy Era Gene therapy can spare people with sickle cell disease from recurrent vaso-occlusive crises, but for the populations that bear most of the global burden of disease, there’s no pathway to such treatment. 2026-09-24
Cumulative Hematologic Morbidity and Outcomes in Shwachman–Diamond Syndrome In an international cohort of 865 patients, Shwachman–Diamond syndrome was associated with a high risk of myeloid cancer and poor survival. Early hematopoietic stem-cell transplantation for high-risk features had a potential benefit. 2026-09-24
Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal In this planned interim analysis of a randomized trial, first surveillance colonoscopy at 5 years after the removal of high-risk adenomas was noninferior to first colonoscopy at 3 years for the incidence of colorectal cancer. 2026-09-17
|
|
|
| |||
|
[Editorial] Microplastics and cancer: a looming threat?
Microplastics are a growing global concern and have been linked to various health conditions. A study presented by Ilias Dimeas and colleagues at the 2026 European Respiratory Society conference found a higher burden of microplastics in the lungs of patients with lung cancer than in those without cancer. In the study, 70% of 100 people undergoing a bronchoscopy had detectable microplastics in at least one sample, and patients with lung cancer were more likely to have detectable microplastics in their samples than patients without lung cancer. Thu, 01 Oct 2026 00:00:00 -0700
[Comment] Exercise oncology: from trials and guidelines to routine clinical care In oncology practice, there are trade-offs between quality of life and survival for many therapies. Similar trade-offs exist for drug reimbursement based on therapeutic effectiveness, affected population, and cost. Fri, 04 Sep 2026 22:30:01 +0000
[Comment] Looking at cancer burden in Africa through a new lens Cancer remains a leading cause of death and disability globally, with a disproportionate rising burden in Africa.1,2 Effective policy response has been consistently hampered by fragmented and incomplete cancer surveillance data.3 For a long time, there has been an assumption that a global uniform framework for understanding cancer risk factors exists and is applicable universally.4 This concept of harmonised global data is plausible in well structured and well resourced health systems in which research and care systems are integrated—systems that exist mostly in high-income regions. Thu, 01 Oct 2026 00:00:00 -0700
[Comment] Personalised medicine in oncology: inequality aversion in a fast-moving field Personalised medicine has been shown to improve patient care and holds promise to further benefit treatment results. The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research provides an overview of state-of-the-art treatments and the situation in low-income and middle-income countries (LMICs). From targeted treatment using companion diagnostics, identifying targets to guide treatment decisions, to broad ‘omics testing in cancer of unknown primary and metastasised tumours, the field is vast and inequalities exist within and between countries. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Ethical priorities in global cancer genomics and precision oncology Amid the promise of cancer genomics and precision oncology lies complex and ethically weighty issues. Genomics and other ‘omics are undoubtedly transforming cancer care for thousands of patients annually, enabling better prognosis, access to treatments or trials, or informing relatives. Yet, these interventions overwhelmingly benefit people in high-income countries: they are failing to reach most patients with cancer who could benefit, and those who are reached could, for reasons including health system readiness or data representation and interpretation, receive no or marginal benefit to their care. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Inequities in access to precision oncology: shared challenges, unified blueprint Precision oncology has substantially changed the therapeutic landscape from a “one size fits all” approach to that of individualised (or personalised) treatments.1 The promise of precision oncology extends across the entire cancer continuum from prevention, early diagnosis, subtyping of tumours, treatment selection, risk-adapted therapies, development of novel anticancer medicines, and post-treatment surveillance.2 The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research focuses on the current challenges and practical solutions to faciliate wider implementation. Fri, 25 Sep 2026 03:10:27 +0000
[Comment] Beyond the evidence: why multistakeholder cooperation will determine whether cancer genomics reaches patients The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology presents a worrying picture.1 While the number of precision oncology drugs continues to increase,2,3 access to testing and matched therapies remains profoundly unequal, research is concentrated in high-income countries (HICs) and populations of European ancestry, and expanding testing capacity has not always translated into proportionate population-level benefit. The Commission's survey of national cancer control programmes (NCCPs), conducted in collaboration with the Union for International Cancer Control and WHO International Agency for Research on Cancer (IARC) across 34 countries, found partial integration of genomics into most NCCPs, including in HICs. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Ecological neglect: critical oversight in precision oncology governance The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research1 examines the gap between the promise of precision oncology and its delivery across global health systems. Raffaella Casolino and colleagues argue that precision oncology has advanced with remarkable speed, yet its clinical impact and sustainability remain uneven, meaning that for much of the world, precision oncology remains just a promise. The authors argue that if the vision of precision oncology is to be realised, health systems need to generate, integrate, govern, and learn from data. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Affordability in the era of precision oncology Cancer drugs are increasingly unaffordable for health systems. Global spending on cancer drugs will reach US$441 billion by 2029.1 This 75% increase over 5 years cannot be explained by population ageing or changing prevalence alone. Instead, the price of cancer drugs is driving accelerated spending growth.2 Rising prices place considerable pressure on health systems, particularly when increased spending is not matched by commensurate improvements in patient health. Unfortunately, many expensive cancer drugs have highly uncertain safety and efficacy evidence at the time of market authorisation. Fri, 25 Sep 2026 03:10:03 +0000
[Comment] Counting who was not tested: artificial intelligence extraction of genomic and treatment data from hospital records The Lancet Oncology Commission on accelerating equitable access to cancer genomics and precision oncology provides an important framework defining indicators that health systems can and should measure.1 Operationalising these indicators, however, requires substantial data infrastructure. One indicator in the Commission's Precision Oncology Access Cascade defines the group of eligible patients who receive recommended genomic testing. The number of patients tested is relatively straightforward to obtain; however, the number meeting the guideline criteria is not because this information is usually recorded as unstructured narrative text rather than as a structured field. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Blank spaces on the map: genomics for global cancer research For most of the history of cancer genomics, the map of our knowledge has had blank spaces on it. In the Pan-Cancer Analysis of Whole Genomes, for example, roughly three quarters of donors were of European descent; samples from Latin American donors made up only about 1% of the large public repositories and samples from patients of Middle Eastern descent were almost entirely absent.1 Thu, 01 Oct 2026 00:00:00 -0700
[Comment] England's National Cancer Plan; ambition without accountability Publication of England's National Cancer Control Plan (NCCP) in February, 2026,1 marked a hard-won achievement, after years of advocacy from patients, clinicians, charities, parliamentarians, and The Lancet Oncology.2,3 The expectation was to address long-standing systemic issues in treatment delays and quality, workforce shortages, and inequalities; but hopes were quickly dashed.4 The plan had no real new money, no additional workforce capacity, no expansion of treatment infrastructure, no prioritisation, and no implementation strategy. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer We read with great interest the Article by Theodore L DeWeese and colleagues detailing the results of the PrTK03 phase 3 trial, which evaluated the addition of aglatimagene besadenovec (CAN-2409) and valacyclovir to standard-of-care external beam radiation therapy (EBRT) for localised prostate cancer.1 We commend the investigators for executing this decade-spanning study. The biological premise—using an adenoviral vector to exert localised cytotoxicity of a systemically administered prodrug while stimulating a T-cell-mediated immune response—is scientifically sound. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer – Authors' reply We thank Thomas Büttner and colleagues for their interest in our Article on the PrTK03 trial.1 In our trial, disease-free survival was the prospectively specified, US Food and Drug Administration-agreed primary endpoint under a Special Protocol Assessment, analysed in the intention-to-treat population and defined to include local failure, including positive biopsy, regional failure, distant metastasis, or death.1 The US Food and Drug Administration did not agree to use biochemical failure as a disease-free survival event. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues’ post-hoc analysis of the PACIFIC trial in The Lancet Oncology addresses an important and clinically timely question: whether baseline exposure to proton pump inhibitors or antibiotics modifies the benefit of durvalumab after concurrent chemoradiotherapy in patients with unresectable stage III non-small-cell lung cancer.1 The observed association between proton pump inhibitor exposure and inferior progression-free and overall survival in the durvalumab group, but not in the placebo group, is thought provoking. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC I read with great interest the Article by Leonardo Brunetti and colleagues,1 which reported that baseline exposure to proton pump inhibitors was associated with substantially inferior progression-free and overall survival among patients receiving durvalumab after concurrent chemoradiotherapy in the PACIFIC trial, but not among those receiving placebo. The use of a randomised, placebo-controlled dataset to separate prognostic from predictive associations is a genuine advance over observational literature. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues report an important post-hoc analysis of the PACIFIC trial,1 showing that baseline exposure to proton pump inhibitors, and to a lesser extent antibiotics, was associated with inferior survival outcomes following durvalumab, but not placebo, in patients with unresectable stage III non-small-cell lung cancer (NSCLC). The randomised placebo-controlled setting and differential analysis across the treatment group are major strengths. Nevertheless, proton pump inhibitor exposure itself was not randomised, and the clinical context in which proton pump inhibitors were prescribed could be crucial to interpretation. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues report an association between proton pump inhibitor exposure and shorter overall survival among patients receiving consolidation durvalumab, but not placebo, in the PACIFIC trial, and propose gut dysbiosis as a potential underlying mechanism.1 We seek clarification on one aspect of the analysis and propose an alternative explanation. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC – Authors' reply We thank our colleagues for their thoughtful comments on our post-hoc analysis of PACIFIC.1 Their correspondence raises two issues: the definition of survival events and whether proton pump inhibitor exposure is causal or reflects its prescribing context. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 181–90 Tang C, Sherry AD, Hwang H, et al. Lancet Oncol 2026; 27: 181–90—In this Article, in the Baseline castration sensitivity row of table 2, the data for patients who are castration resistant and those who are castration sensitive were reversed. This correction has been made to the online version as of Sept 3, 2026. Thu, 03 Sep 2026 22:30:00 +0000
[Corrections] Correction to Lancet Oncol 2026; 27: 1043–56 Brunetti L, Santo V, Pinato DJ, et al. Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. Lancet Oncol 2026; 27: 1043–56—The appendix of this Article has been corrected as of Sept 28, 2026. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 1077–93 Kudo M, Abou-Alfa GK, Ren Z, et al. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol 2026; 27: 1077–93—In this Article, sentence eight of the Findings in the Summary should have read ‘post-embolisation syndrome’. In the Outcomes section of the Methods, the disease control rate at 20 weeks explanation has been corrected. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 1094–109 Le X, Passaro A, Zhao Y, et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2026; 27: 1094–109—In this Article, the second and third sentences of the ninth paragraph of the Results section should have read “The most common immune-related treatment-related adverse events of any grade in the ivonescimab plus chemotherapy group were hypothyroidism (18 [8%]) and hyperthyroidism (nine [4%]), and in the placebo plus chemotherapy group were rash (seven [3%]), alanine aminotransferase increased (seven [3%]), aspartate aminotransferase increased (six [3%]), and amylase increased (six [3%]). Thu, 01 Oct 2026 00:00:00 -0700
[News] Trump cuts childhood vaccine recommendations The US President Donald Trump has issued an executive order stressing “maximal parental choice” and cutting the number of childhood vaccines recommended by the federal government to 11 from 18. Thu, 20 Aug 2026 22:30:04 +0000
[News] Nigeria plans major expansion of radiotherapy capacity Africa's most populous country Nigeria plans to procure and install 35 additional linear accelerators (LINACs), substantially expanding its radiotherapy capacity. Six Cancer Centres of Excellence are also being developed, with centres in Katsina, Enugu, and Benin completed and commissioned. However, the new machines translating into wider access depends on availability of specialist staffing, maintenance, financing, and where the additional capacity is located. Thu, 20 Aug 2026 22:30:01 +0000
[News] Delays in cancer referrals and care lead to harm and missed diagnoses in England Late and missed diagnoses, delays in cancer care, and physical harm were partly caused by England's National Health Service (NHS) system for general practitioners (GPs) seeking specialist advice before patient referral to hospital, according to an investigation by the Health Services Safety Investigations Body (HSSIB). Thu, 27 Aug 2026 22:30:01 +0000
[News] Increased tobacco production and cigarette imports in Africa While tobacco-leaf production across the world declined by 19% between 2012 and 2024, it increased by 9% in Africa, according to a WHO analysis published on Aug 31, 2026. Moreover, during this period, there was a more than two-times increase in cigarette imports to Africa—from US$833 million to $1·77 billion. Thu, 10 Sep 2026 22:30:01 +0000
[News] 2026 World Conference on Lung Cancer Interim results from the phase 3 ARTEMIS-008 trial, presented by Jie Wang (Chinese Academy of Medical Sciences, Beijing, China), suggest risvutatug rezetecan, a B7-H3-directed antibody–drug conjugate (ADC), could be the new standard of care in relapsed small-cell lung cancer (SCLC). Patients were randomly assigned (1:1) to receive risvutatug rezetecan (8·0 mg/kg; n=230) or topotecan (1·2 mg/m2 on days 1–5; n=231) every 3 weeks. At a median follow-up of 12·2 months, overall survival (the primary endpoint) was significantly improved with risvutatug rezetecan compared with topotecan (18·5 vs 10·3 months; HR 0·46 [95% CI 0·35–0·62). Thu, 17 Sep 2026 22:30:02 +0000
[News] Kenya agrees major cuts to cancer drug prices The Kenyan Government has agreed a deal with Pfizer that could reduce the price of selected cancer medicines by seven times. Costs are expected to drop from as much as 1 million Kenyan Shillings (KSh; US$7725) to below KSh50 000 ($386) per treatment cycle for some drugs. The agreement covers nine cancers: breast, stomach, colorectal, lung, prostate, and oesophageal cancers, as well as leukaemia, lymphoma, and multiple myeloma. Thu, 17 Sep 2026 22:30:01 +0000
[News] Toxic dust around the World Trade Center On Sept 8, 2026, New York City authorities released more than 170 000 pages of documents showing that officials misled the public about toxic air quality levels after the Sept 11, 2001, attack that killed more than 2600 people at the World Trade Center (WTC). Health researchers say the documents contain little medical information that is new but confirm that carcinogens and toxins were present months after the attacks, exposing 400 000 people in lower Manhattan to smoke, dust, and combustion products. Thu, 17 Sep 2026 22:30:02 +0000
[Perspectives] Cancer's new anxiety: not a death sentence, but delay Throughout the history of cancer research, hyperbole has never been in short supply—whether it be Richard Nixon's war, Joe Biden's moonshot, or Cancer Research UK's 2023 declaration of a golden era. Driving such rhetoric has been the need to act against an enduring societal concern—cancer, the so-called Big C, society's number one fear. Thu, 01 Oct 2026 00:00:00 -0700
[Perspectives] Against cancer, not against dying: Ernest Becker in the oncology clinic When American cultural anthropologist Ernest Becker was awarded the 1974 Pulitzer Prize for his book, The Denial of Death, he had died of colorectal cancer only 2 months earlier. More than half a century later, the book feels almost uncomfortably contemporary in the oncology clinic. Although the book does not address cancer care directly, it speaks to what cancer reveals: mortality, and the symbolic structures we build to make that knowledge bearable. For Becker, identities, professions, institutions, religions, families, reputations, and achievements are ways in which the fragile self seeks continuity beyond finitude. Thu, 01 Oct 2026 00:00:00 -0700
[Perspectives] Sir Chris Hoy's Tour de 4 charity cycle ride returns Mention the name Chris Hoy and it's natural to picture the Olympic cyclist, who won six gold medals and one silver in Sydney, Athens, Beijing, and London between 2000 and 2012. Fans voted for him to be named as the BBC Sports Personality of the Year in 2008, and he was knighted by the late Queen Elizabeth in the 2009 New Year honours list. However, over the past 2 years, Hoy has become famous for a completely different reason. In October, 2024, he revealed that he had received a terminal diagnosis of stage-4 prostate cancer, which had spread to his bones. Sun, 06 Sep 2026 23:01:02 +0000
[Perspectives] Differing approaches to cancer at the Edinburgh Fringe “I had cancer a couple of years ago—I don’t like to talk about it,” grinned comedian Matt Forde during his show at the Edinburgh Festival Fringe, the world's largest arts festival, which took place in Edinburgh, UK, on Aug 7–31, 2026. With a sly grin at his audience, he added “I’m not going to use it to sell tickets for another sold out night in Edinburgh.” Forde, who is best known for his impressions of politicians, was diagnosed in July, 2023, with a chordoma, a very rare sarcoma at the base of his spine. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial Pembrolizumab plus chemotherapy followed by maintenance with pembrolizumab–olaparib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy, suggesting that this regimen might have potential for patients with newly diagnosed BRCA non-mutated stage III–IV epithelial ovarian cancer. Mon, 07 Sep 2026 22:30:04 +0000
[Articles] Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis Our findings highlight the importance of infection control to achieve cancer prevention. Scientifically proven, but often underused, approaches include HPV and HBV vaccination; testing and treatment of HIV, H pylori, HBV, and HCV; safe injection practices; access to condoms and pre-exposure prophylaxis to prevent HIV transmission; and screening of precancerous lesions for HPV-driven cervical and anal cancer. Our findings also inform the investment cases for research and development for new prevention tools, most notably for EBV. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial Hypofractionated postmastectomy radiotherapy provided durable locoregional control with no increase in severe late adverse events compared with conventional fractionation, supporting its use as a more time-efficient option than conventional fractionated radiotherapy. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial Weekly PRO symptom monitoring was associated with meaningful improvement in long-term overall survival among patients with stage I–IV lung cancer. Median overall survival was 5 months longer in the intervention group than in the control group. These findings underscore the value of implementing PRO symptom monitoring within routine care for patients with lung cancer. Fri, 11 Sep 2026 22:30:01 +0000
[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial OPTIMUM shows sustained progression-free survival and overall survival improvement with risk-stratified extended therapy, supporting implementation of molecular diagnostics and tailored treatment in patients with newly diagnosed high-risk multiple myeloma. Mon, 07 Sep 2026 22:30:01 +0000
[Articles] An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial The STAMINA lifestyle intervention meets best practice guidelines, can be implemented in NHS trusts in England, and offers clinicians a clear basis for identification and prescription of a supervised exercise and dietary advice intervention to mitigate negative effects associated with ADT. Fri, 04 Sep 2026 22:30:01 +0000
[Articles] Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era The CPI2 model, using 14 readily available clinical parameters, demonstrated improvement in discriminative accuracy compared with the IMDC model. This classification should be further validated in other trial and observational populations and be used to reanalyse heterogeneity of treatment effects of immune checkpoint inhibitor-based combination regimens in trials shaping the current and future treatment landscape. Wed, 09 Sep 2026 22:30:01 +0000
[Articles] Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study Wildfire-related PM2·5 showed greater toxicity per unit exposure than non-wildfire PM2·5. As wildfire-related PM2·5 is the fastest-growing contributor to ambient air pollution, there is an urgent need for updated strategies to manage wildfires and mitigate their effects. Tue, 15 Sep 2026 22:30:01 +0000
[Articles] Burden of cancer in Africa, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023 Cancer is a growing contributor to the disease burden in Africa, with rising cases, deaths, and DALYs disproportionately affecting children, adolescents, and young adults. The increase in age-standardised mortality and DALY rates stands in sharp contrast to the ambitions of the Sustainable Development Goals for 2030 and the African Union Agenda 2063. Addressing this burden will require coordinated national and international action, with health-system strengthening and context-specific cancer-control strategies spanning prevention, early diagnosis, and treatment. Tue, 15 Sep 2026 22:30:01 +0000
[The Lancet Oncology Commission] Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Cancer genomics and precision oncology are increasingly central to cancer care, but many health systems struggle to implement them equitably, effectively, and sustainably. This Commission defines the current global precision oncology landscape and analyses the scientific, structural, and health-system challenges shaping its delivery and impact. Findings indicate that access to cancer genomics and precision oncology remains profoundly unequal across and within countries, leaving millions of patients without guideline-indicated interventions each year. Fri, 25 Sep 2026 03:10:28 +0000
[Policy Review] Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population Cancer susceptibility testing is rapidly advancing beyond specialist genetics clinics into routine oncology and population-level genomics initiatives. This expansion positions germline pathogenic variants in cancer susceptibility genes and polygenic risk scores as crucial tools for precision prevention, surveillance, and early detection. However, implementation has outpaced the evidence needed to justify testing at scale, particularly in well populations. For a small number of first-wave genes—including BRCA1, BRCA2, MLH1, and MSH2—cancer risks are well established and downstream medical interventions are supported by substantial observational evidence, albeit with an absence of randomised trials. Fri, 25 Sep 2026 03:10:02 +0000
[Review] Cancer and the microbiome: from association to intervention The gut microbiome is increasingly recognised as a clinically modifiable determinant of efficacy and toxicity across systemic cancer therapies, with the most mature evidence in patients receiving immune checkpoint inhibitors (ICIs). The composition and function of intestinal microbes can influence treatment outcomes by affecting immune priming, antigen presentation, host–microbial co-metabolism, drug biotransformation, and epithelial barrier integrity. In melanoma, non-small-cell lung cancer, and renal cell carcinoma, higher microbial diversity, ecological stability, and enrichment of immunostimulatory pathways have been associated with improved ICI response and survival. Thu, 01 Oct 2026 00:00:00 -0700
[Clinical Picture] Not all thoracic micronodules are metastases A 58-year-old female, lifelong non-smoker with history of Parkinson's disease, presented with a palpable right breast lump to the Odette Cancer Centre at Sunnybrook Health and Sciences Centre (Toronto, ON, Canada) in April, 2024, and was diagnosed with right-sided oestrogen receptor-positive, HER2-positive breast cancer (cT3N0). She received neoadjuvant dose dense doxorubicin–cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab. Lumpectomy and sentinel lymph node biopsy was performed revealing a pathological complete response. Thu, 01 Oct 2026 00:00:00 -0700
|
Real‐world outcomes in circulating tumor DNA–detected isocitrate dehydrogenase 1–mutant cholangiocarcinoma: First‐line gemcitabine and cisplatin with versus without immunotherapy
In IDH1+ aCCA, addition of immunotherapy to GemCis was associated with inferior rwOS. These findings support obtaining ctDNA‐based CGP before initiating 1L therapy, and underscore the need for prospective studies. Wed, 14 Oct 2026 22:24:06 -0700 Blood‐based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG‐GY012 IL‐6 may be predictive of outcome; OPN and PlGF represent novel potential predictive biomarkers, in EC patients receiving anti‐angiogenic therapy. Further evaluation is warranted. Wed, 14 Oct 2026 00:00:00 -0700 Cancer risks associated with BRCA1 and BRCA2: Overview and management Wed, 14 Oct 2026 00:00:00 -0700 Evaluation of early C‐reactive protein kinetics as an early response marker in biliary tract cancer treated with combined chemoimmunotherapy: A multicenter observational study CRP kinetics may be a valuable prognostic tool for early response assessment in patients with BTC who receive chemoimmunotherapy. However, these findings require prospective external validation in larger cohorts. Tue, 13 Oct 2026 00:00:00 -0700 Increased risk of stroke after a new cancer diagnosis—Where are the knowledge gaps currently? Tue, 13 Oct 2026 00:00:00 -0700 Evolving role of proton therapy in contemporary oncology Tue, 13 Oct 2026 00:00:00 -0700 Delays in breast cancer presentation, diagnosis, and treatment in young women In this cohort of young patients with BC, demographic and tumor factors were associated with delays in care. It is reassuring that delays did not influence disease outcomes. Mon, 12 Oct 2026 00:00:00 -0700 Who is eligible for lung cancer screening, and where are they? National subpopulation estimates of people eligible for lung cancer screening Fri, 09 Oct 2026 00:00:00 -0700 Perceived risk of survivorship sexual dysfunction Thu, 08 Oct 2026 00:00:00 -0700 Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer Wed, 07 Oct 2026 00:00:00 -0700 Perioperative immunotherapy in head and neck squamous cell carcinoma Wed, 07 Oct 2026 00:00:00 -0700 Issue Information Tue, 06 Oct 2026 06:03:21 -0700 Redefining leptomeningeal metastasis in non–small cell lung cancer: From terminal complication to molecularly managed disease Tue, 06 Oct 2026 00:00:00 -0700 Targeting RAS in pancreatic cancer Tue, 06 Oct 2026 00:00:00 -0700 |
Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial
This randomized clinical trial examines the relationship between digital patient-reported outcome monitoring with alert-based responses and fatigue in patients with metastatic breast cancer. Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer This retrospective modeling and validation study uses clinical trial data to develop mathematical biomarkers that predict outcomes of patients with prostate cancer undergoing adaptive therapy. Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer This cohort study examines the occurrence and rate of metabolic syndrome during the first year following initiation of androgen deprivation therapy–androgen receptor pathway inhibitor. Trends in Meningioma Incidence, Treatment, and Imaging Surveillance This quality improvement study examines incidence, treatment, and surveillance patterns in meningioma care in Denmark from 2010 to 2023 to identify potentially unnecessary follow-up imaging. Federal and Industry Sponsorship in US Cancer Clinical Trials This comparative study of cancer clinical trial portfolios assesses differences between federal and industry sponsors in cancer clinical trial research. Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients This cohort study assesses market dynamics and examines financial implications associated with biosimilar use patterns among patients who received bevacizumab, rituximab, or trastuzumab. Racial and Ethnic Disparities in US Colorectal Cancer Mortality by County, Sex, and Age This cross-sectional study assesses variation in colorectal cancer mortality rates and changes over time across county, race and ethnicity, sex, and age in the US. Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review This narrative review discusses chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage breast cancer. Oral Ulcers in a Patient With Myelodysplastic Syndrome A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? Redefining Progression in a Rapidly Evolving Therapeutic Landscape This Viewpoint the regulatory problem of how to design clean trials that regulators seek as the field of oncology becomes more therapeutically sophisticated. Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment. Academy of QI—Learning Leadership by Quality Improvement This Viewpoint discusses the strong connection between quality improvement and leadership development. Managing Metabolic Syndrome and Prostate Cancer Supplements and Wellness Products During Cancer Care This Hindsight Bias in Diagnosis This essay discusses the public discourse around “missed” diagnoses and how physicians should engage patients early in diagnostic reasoning. Overlapping Cohorts and Double Counting in Meta-Analyses Overlapping Cohorts and Double Counting in Meta-Analyses—Reply Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability—Reply Adult T-Cell Leukemia/Lymphoma and Maternal Screening Adult T-Cell Leukemia/Lymphoma and Maternal Screening—Reply JAMA Oncology |
|
|
| |||
|
[Editorial] Personalising AML treatment: beyond age and fitness
Over the past couple of decades, the number of treatment options for patients with acute myeloid leukaemia has accelerated; however, most patients still do not survive long-term, with 5-year overall survival around 30%. For younger and functionally fit patients, the predominant front-line therapy has remained unchanged for half a century: intensive induction chemotherapy that includes cytarabine and anthracyclines (the 7+3 regimen). For older patients or those not able to undergo intensive chemotherapy, a combination of hypomethylating agent and venetoclax is now the standard front-line therapy, spearheaded by the VIALE-A trial in 2020. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia Nicolò Peccatori and colleagues provide evidence for inotuzumab ozogamicin in paediatric very-high-risk first-relapse B-cell acute lymphoblastic leukaemia.1 The data support a less toxic bridge to haematopoietic stem cell transplantation (HSCT), but the response denominators support a more specific clinical interpretation: inotuzumab ozogamicin is best viewed as cycle-1 molecular triage, not prolonged reinduction or a replacement for UK ALLR3 chemotherapy. Because ITCC-059 was a single-arm study and its statistical design was modified from 43 to 31 patients while increasing the alpha-error to 10%, comparative claims should be reframed as response-adapted sequencing. Wed, 09 Sep 2026 22:30:04 +0000
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply We appreciate discussing the ITCC-059 results in response to Xiaogang Hao and colleagues. Wed, 09 Sep 2026 22:30:01 +0000
[In Focus] From approval to practice: are clinicians and health systems ready for gene therapy in sickle cell disease? Once a scientist's dream, gene therapy for sickle cell disease has now entered clinical practice. Autologous gene-based therapies offer a potential curative option for a disease that affects approximately 7·7 million people worldwide and remains associated with substantial morbidity, premature mortality, and entrenched health inequities. Regulatory approval, however, represents only the first step in a much longer translational pathway. Experience from other high-cost innovations suggests that without concurrent investment in implementation, workforce preparation, and financing, access could remain uneven or delayed. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Vernon Louw: expanding access to clinical haematology in Africa Vernon Louw was not that interested in haematology at first. As an undergraduate he had found the teaching “very laboratory based” and he “struggled to connect it with the patients behind the results”. This sentiment changed when he began treating patients with haematological malignancies as a registrar in internal medicine. “I came to appreciate that haematology combines complex diagnostic reasoning, laboratory science, and long-term relationships with patients in a particularly compelling way”, he recalled. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Integrating sexual health into sickle cell disease care Sexual health is a fundamental component of overall wellbeing, yet it remains one of the least addressed dimensions of care for people living with sickle cell disease. At the ASCAT 2025 meeting in London, UK, ERN-EuroBloodNet and RADeep registry convened a 3-day patient educational workshop dedicated to this topic. The sessions brought together 27 people living with sickle cell disease and a multidisciplinary team comprising one obstetrician, one internist, two haematologists, and two psychologists, creating an intergenerational and intercultural space, with 13 countries represented to exchange perspectives. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2) To our knowledge, this is first clinical study of a Bruton tyrosine kinase inhibitor, rilzabrutinib, in warm autoimmune haemolytic anaemia. Rilzabrutinib showed robust overall and durable haemoglobin response and favourable safety in patients with previously treated warm autoimmune haemolytic anaemia. Rilzabrutinib has the potential to treat the underlying pathophysiology of warm autoimmune haemolytic anaemia through multi-immune modulation, induce a robust and sustained haemoglobin response, and provides an opportunity to decrease or stop corticosteroid use. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial Rilzabrutinib showed continued, stable, and sometimes improved platelet responses, including in patients who were initially non-responsive in the double-blind trial. Additionally, rilzabrutinib improved several disease aspects, including physical fatigue and bleeding, supporting its multi-immune modulation mechanism in immune thrombocytopenia, and had a favourable safety profile. The long-term extension period of LUNA3 will further characterise the long-term efficacy and safety of rilzabrutinib in patients with difficult-to-treat immune thrombocytopenia, and the ongoing LUNA4 trial (NCT07007962) will determine the efficacy of rilzabrutinib in earlier-line treatment and its potential to achieve sustained treatment-free response. Thu, 17 Sep 2026 22:30:01 +0000
[Articles] Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial Felzartamab plus lenalidomide–dexamethasone significantly prolonged progression-free survival compared with lenalidomide–dexamethasone alone, supporting felzartamab plus lenalidomide–dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial Topical ruxolitinib showed significant clinical activity and favourable harms profile in active cutaneous cGVHD. Ruxolitinib cream could represent a steroid-sparing, skin-directed alternative or second-line therapy, expanding treatment options for patients with cutaneous cGVHD. Wed, 16 Sep 2026 22:30:02 +0000
[Review] High time for risk-adapted treatment in mantle cell lymphoma Mantle cell lymphoma has multiple treatment options, yet the disease is difficult to cure. Relapses are common, treatments can cause severe side-effects, and current recommendations are still largely based on age rather than biology. Although suitability for intensive treatment was previously the decisive parameter, increasing knowledge on the biology of mantle cell lymphoma and less toxic targeted therapies has made non-risk adapted treatments outdated. TP53 mutations or deletions, blastoid histology, and a high Ki-67 proliferation index consistently identify patients at high risk of relapse. Wed, 02 Sep 2026 22:30:01 +0000
[Review] At the heart of unmet need: TP53 myeloid neoplasms TP53 myeloid neoplasms are being increasingly encountered in clinical practice and have been recognised in 2022, as a unique entity in the setting of functional loss of the two copies of the gene. The classification of myeloid neoplasm based on presence of biallelic (multi-hit) TP53 should precede morphological classification. The identification of biallelic (multi-hit) inactivation continues to evolve and is a matter of great debate balancing definitive biallelic identification via assays, pathology classifications, and clinical applicability. Thu, 01 Oct 2026 00:00:00 -0700
[Personal View] Redefining plasma cell leukaemia Plasma cell leukaemia is an aggressive plasma cell malignancy characterised by the presence of a high percentage of circulating clonal plasma cells on conventional peripheral blood smear examination. We argue that plasma cell leukaemia must no longer be considered as a separate disease entity but as a type of high-risk multiple myeloma. With the adoption of more strict criteria for defining high-risk multiple myeloma and the relaxation of criteria in defining plasma cell leukaemia, the clinical implications of the terms have converged. Fri, 21 Aug 2026 22:30:01 +0000
|
Hematopoietic stem cell culture comes of age
As part of our series “Evolving Paradigms in Hematology,” this editorial by Adam Wilkinson and Associate Editor Berthold Göttgens highlights how recent advances in hematopoietic stem cell (HSC) culture technology offer unprecedented opportunities for actively programming and interrogating HSCs for therapeutic gain, as well as interrogating fundamental biology.
Volume 148, Issue 16 October 15 2026 Neurotoxicity with CAR T cells in myeloma deciphered? Volume 148, Issue 16 October 15 2026 The enigma of rapid response vs safety in AL amyloidosis Volume 148, Issue 16 October 15 2026 T cells targeting immunoglobulin in myeloma: a way forward? Volume 148, Issue 16 October 15 2026 Untangling the ties that bind: the NG2-ITGA4 axis in B-ALL Volume 148, Issue 16 October 15 2026 Myelofibrosis end points and self-evident truths Volume 148, Issue 16 October 15 2026 Bone marrow ménage à trois balances neutrophil production Volume 148, Issue 16 October 15 2026 Taking the brakes off cytolytic CD4+ T cells Volume 148, Issue 16 October 15 2026 Ironing out vascular control in anemia Volume 148, Issue 16 October 15 2026 Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma B-cell maturation antigen–directed chimeric antigen receptor (CAR) T cells are changing the landscape of care for patients with relapsed multiple myeloma, but neurological toxicity remains an issue. In this month’s CME article, Hosoya and colleagues reveal that ciltacabtagene autoleucel (cilta-cel) is associated with higher CAR T-cell expansion than idecabtagene vicleucel and that absolute lymphocyte count (ALC) is a reliable surrogate measure for this. Greater CAR T-cell expansion reflected in a rapid ALC rise to higher levels can predict for delayed neurotoxicity, setting the scene for interventional studies testing whether strategies based on ALC rise can prevent these potentially devastating toxicities.
Volume 148, Issue 16 October 15 2026 A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis For most patients with light-chain (AL) amyloidosis, the standard initial treatment is Dara-VCd (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) induction, followed by Dara maintenance. But the sickest patients, those with significant cardiac involvement, do not tolerate the regimen and have a 40% early death rate. Kastritis et al report the results of a phase 2 trial of Dara monotherapy as initial therapy, with selective introduction of bortezomib plus dexamethasone for patients without a major response after 3 cycles. They found both excellent tolerability and efficacy, including a 30% cardiac response rate. This regimen can be recommended for patients with stage IIIb AL amyloidosis based on this evidence.
Volume 148, Issue 16 October 15 2026 TCR T cells targeting IgA- and IgG-expressing multiple myeloma In multiple myeloma, malignant plasma cells uniformly and consistently express isotype-specific immunoglobulin heavy chain (IgH). Parallel studies by Douvlataniotis et al and Meeuwsen et al explore a strategy of adoptive T-cell therapy using T-cell receptors (TCRs) targeting peptides derived from the constant regions of IgH as an alternative to targeting cell surface antigens. They demonstrate HLA-restricted killing of IgA or IgG myeloma cells but not normal plasma cells of other isotypes by allogeneic isotype-specific TCR T cells in vitro and in vivo, positioning these types of product for assessment in clinical trials.
Volume 148, Issue 16 October 15 2026 Immunoglobulin constant domains as targets for T-cell receptor–based treatment of multiple myeloma In multiple myeloma, malignant plasma cells uniformly and consistently express isotype-specific immunoglobulin heavy chain (IgH). Parallel studies by Douvlataniotis et al and Meeuwsen et al explore a strategy of adoptive T-cell therapy using T-cell receptors (TCRs) targeting peptides derived from the constant regions of IgH as an alternative to targeting cell surface antigens. They demonstrate HLA-restricted killing of IgA or IgG myeloma cells but not normal plasma cells of other isotypes by allogeneic isotype-specific TCR T cells in vitro and in vivo, positioning these types of product for assessment in clinical trials.
Volume 148, Issue 16 October 15 2026 The NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab KMT2A-rearranged (KMT2A-r) B-cell acute lymphoblastic leukemia (B-ALL) carries a poor prognosis despite recent advances in therapy. Rubio-Gayarre and colleagues explored upregulation of the membrane-bound proteoglycan neuron-glial antigen 2 (NG2) in these leukemias. NG2 acts as a scaffold to recruit Rho GTPase regulatory proteins downstream of α4 integrin (ITGA4) signaling, promoting leukemia progression and disease aggressiveness. The authors show that the ITGA4-binding monoclonal antibody natalizumab delays leukemia progression and potentiates the efficacy of standard-of-care chemotherapy in KMT2A-r B-ALL patient-derived xenograft models, suggesting that repurposing of this drug may have a future role in therapy for this leukemia subtype.
Volume 148, Issue 16 October 15 2026 TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis The JAK inhibitors reduce splenomegaly and improve symptom control in patients with myelofibrosis, but usually they do not modify the underlying disease process. Myeloproliferative neoplasms display dependence on BCLxL, leading to the study of navitoclax, a dual BCL2/BCLxL inhibitor, with promising results suggesting disease modification in early-phase trials in combination with ruxolitinib. Pemmaraju et al report a phase 3 randomized trial of navitoclax versus placebo, finding that, while navitoclax doubles the spleen response and generates greater reductions in the variant allele frequency of mutant JAK2, there is no improvement in symptom scores and there is more hematological toxicity. These data highlight the challenges to drug development for this disease.
Volume 148, Issue 16 October 15 2026 Erythroblast-derived lipid mediators program neutrophil development and function Specialized proresolving mediators (SPMs) are short-lived, short-ranged lipid signals derived from ω-3 fatty acids. They are known to regulate inflammation resolution and promote tissue repair, partly by restraining emergency myelopoiesis. Using elegant genetic murine models, Koenis et al demonstrate that erythroblasts produce SPMs that instruct macrophages expressing GPR101, a proresolving lipid receptor, to support balanced development and function of neutrophils. These data identify erythroblasts as immunomodulatory cells within the bone marrow niche.
Volume 148, Issue 16 October 15 2026 IL-6 receptor inhibition promotes expansion of cytolytic CD4+ T cells after cellular immunotherapy We still have much to learn about the in vivo function of T-cell subsets and how it is modulated, especially in the context of T-cell immunotherapy. Williams and colleagues studied patient samples and murine genetic models to describe a previously unrecognized role for interleukin-6 (IL-6) in suppressing the differentiation of eomesodermin-positive cytolytic and type 1 regulatory CD4+ T cells. Inhibition of IL-6 receptor signaling induces these cells and increases antitumor activity in model systems. These findings suggest strategies to optimize use of drugs such as tocilizumab in the period immediately before T-cell infusion.
Volume 148, Issue 16 October 15 2026 Arterial iron regulates vasodilation during anemia via endothelial holo-α-globin Are the hemodynamic changes observed in iron deficiency anemia solely due to reduced red cell hemoglobin and mass, or does iron insufficiency directly affect the vasculature as well? Dunaway et al reveal that it is the latter. They provide compelling genetic evidence from murine models that endothelial iron deficiency directly alters vascular tone through reduction in α-hemoglobin with consequent increases in nitric oxide signaling and vasodilation of resistance arteries. Intriguingly, this phenomenon is most pronounced in females.
Volume 148, Issue 16 October 15 2026 Optical genome mapping reveals a MYC-amplified ring chromosome arising through chromoanagenesis in AML Volume 148, Issue 16 October 15 2026 Isaac ST, Bishop DC, Shaikh F, Micklethwaite K, Gottlieb DJ, Blyth E. Human herpesvirus 6 viremia and encephalitis in CAR T-cell recipients. Blood. 2025;146(25):3124-3128. Volume 148, Issue 16 October 15 2026 Cilta-cel CAR T-cell expansion and neurotoxicity Volume 148, Issue 16 October 15 2026 |
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Mon, 12 Oct 2026 21:04:54 -0700 Issue Information Mon, 12 Oct 2026 05:55:51 -0700 Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia Mon, 12 Oct 2026 05:55:51 -0700 Primary Plasma Cell Leukemia Mon, 12 Oct 2026 05:55:51 -0700 Myeloma Progression Without Osteolysis: Rethinking Whole‐Body Low‐Dose CT Criteria for Bone Disease Mon, 12 Oct 2026 05:55:51 -0700 Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T‐Cell Therapy Mon, 12 Oct 2026 05:55:51 -0700 Hypomethylating Therapy in VEXAS Syndrome: Disease Modification Beyond Bridging to Transplant Mon, 12 Oct 2026 05:55:51 -0700 Hematopoietic Stem Cell Transplantation in Children With Transfusion Dependent β‐Thalassemia: A Two‐Decade Single‐Center Experience Mon, 12 Oct 2026 05:55:51 -0700 Cognitive Impairment, Depression and Cerebral Microbleeds in Immune Thrombocytopenia (ITP) Mon, 12 Oct 2026 05:55:51 -0700 Real‐World Outcomes of Venetoclax‐Based Therapy in Treatment‐Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study Mon, 12 Oct 2026 05:55:51 -0700 Chronic Anemia Is Associated With Subclinical Myocardial Fibrosis in α‐Τhalassemia Intermedia Mon, 12 Oct 2026 05:55:51 -0700 Efficacy, Safety, and Kinetics of Naturally Selected Anti‐CD7 CAR‐T Cell Therapy in T‐ALL/LBL With CNS Leukemia Mon, 12 Oct 2026 05:55:51 -0700 BiRD Regimen Followed by Anti‐BCMA CAR‐T Cell Immunotherapy as First‐Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single‐Arm, Phase 2 Trial Mon, 12 Oct 2026 05:55:51 -0700 Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial Mon, 12 Oct 2026 05:55:51 -0700 Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy Mon, 12 Oct 2026 05:55:51 -0700 HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities Mon, 12 Oct 2026 05:55:51 -0700 Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care Mon, 12 Oct 2026 05:55:51 -0700 Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS) Mon, 12 Oct 2026 05:55:51 -0700 Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra‐High‐Risk Cytogenetics Mon, 12 Oct 2026 05:55:51 -0700 Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents Mon, 12 Oct 2026 05:55:51 -0700 SHR‐2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study Mon, 12 Oct 2026 05:55:51 -0700 |
|
|
| |||
|
Thrombophilia testing: does it truly affect risk? October 13 2026 - Volume 10, Issue 19 Beyond hemolysis: redefining pediatric AIHA October 13 2026 - Volume 10, Issue 19 New views on VUSs in RUNX1-FPD October 13 2026 - Volume 10, Issue 19 Democratizing cancer risk testing in children before alloHCT October 13 2026 - Volume 10, Issue 19 CC-486 plus venetoclax: another step toward oral AML therapy October 13 2026 - Volume 10, Issue 19 The roots run deep in therapy-related myeloid neoplasms October 13 2026 - Volume 10, Issue 19 Of mice and FVIIIa mimetics: new hemophilia A models for in vivo evaluation October 13 2026 - Volume 10, Issue 19 CATCHing chronic GVHD October 13 2026 - Volume 10, Issue 19 Canadian emicizumab registry: a blueprint for the future October 13 2026 - Volume 10, Issue 19 HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO) October 13 2026 - Volume 10, Issue 19 CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma October 13 2026 - Volume 10, Issue 19 HMA + venetoclax triplet regimens for the initial treatment of AML in adults October 13 2026 - Volume 10, Issue 19 Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma October 13 2026 - Volume 10, Issue 19 Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin October 13 2026 - Volume 10, Issue 19 Burkitt lymphoma: current understanding, unmet needs, and research directions October 13 2026 - Volume 10, Issue 19 Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis October 13 2026 - Volume 10, Issue 19 MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL October 13 2026 - Volume 10, Issue 19 Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL October 13 2026 - Volume 10, Issue 19 Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis October 13 2026 - Volume 10, Issue 19 Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial October 13 2026 - Volume 10, Issue 19 Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia October 13 2026 - Volume 10, Issue 19 A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML October 13 2026 - Volume 10, Issue 19 A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia October 13 2026 - Volume 10, Issue 19 Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826) October 13 2026 - Volume 10, Issue 19 Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML October 13 2026 - Volume 10, Issue 19 Chronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development October 13 2026 - Volume 10, Issue 19 Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry October 13 2026 - Volume 10, Issue 19 Characterization of hematopoietic stem cell–derived microglia-like cells in nonhuman primates October 13 2026 - Volume 10, Issue 19 JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation October 13 2026 - Volume 10, Issue 19 HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL October 13 2026 - Volume 10, Issue 19 CD20 bispecific T-cell engager depletes B-cell progenitors preventing EBV-associated lymphomagenesis in humanized mice October 13 2026 - Volume 10, Issue 19 Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia October 13 2026 - Volume 10, Issue 19 Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial October 13 2026 - Volume 10, Issue 19 Genomic architecture of IRF4 rearrangements in childhood and adult large B-cell lymphomas October 13 2026 - Volume 10, Issue 19 Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma October 13 2026 - Volume 10, Issue 19 Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma October 13 2026 - Volume 10, Issue 19 Functional analysis of germline RUNX1 variants identified in individuals with suspected familial platelet disorder October 13 2026 - Volume 10, Issue 19 Comutation of asxl1 and IDH2R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish October 13 2026 - Volume 10, Issue 19 Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms October 13 2026 - Volume 10, Issue 19 Real-world investigation of germ line predisposition to myelodysplastic syndromes October 13 2026 - Volume 10, Issue 19 Rapid and reproducible karyotyping with long-read sequencing in patients with AML October 13 2026 - Volume 10, Issue 19 A prospective study of familial predisposition to plasma cell dyscrasias October 13 2026 - Volume 10, Issue 19 Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma October 13 2026 - Volume 10, Issue 19 Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations October 13 2026 - Volume 10, Issue 19 Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders October 13 2026 - Volume 10, Issue 19 Characterization of a mouse model to study mechanisms of hemophilia A pain October 13 2026 - Volume 10, Issue 19 Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP October 13 2026 - Volume 10, Issue 19 Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase October 13 2026 - Volume 10, Issue 19 A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies October 13 2026 - Volume 10, Issue 19 Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States October 13 2026 - Volume 10, Issue 19 In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway October 13 2026 - Volume 10, Issue 19 Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantation October 13 2026 - Volume 10, Issue 19 Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis October 13 2026 - Volume 10, Issue 19 Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant October 13 2026 - Volume 10, Issue 19 Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights October 13 2026 - Volume 10, Issue 19 Hydroxyurea reduces hyperadhesion measured by a VLA-4–targeting PET tracer in sickle transgenic Townes mice October 13 2026 - Volume 10, Issue 19 Donor-targeted anti–HLA-A2 antibody shows nanogram-level efficacy in a novel GVHD mouse model October 13 2026 - Volume 10, Issue 19 Are statins interferon’s best friends? Mechanistic insights October 13 2026 - Volume 10, Issue 19 Potential mechanisms of statin and interferon-α2 therapy October 13 2026 - Volume 10, Issue 19 Yu H, Schroeder JA, Mattson JG, Gao C, and Shi Q. Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice. Blood Adv. 2026;10(6):1883-1896. October 13 2026 - Volume 10, Issue 19 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Long-Acting HIV Therapy in African Adults with Adherence Challenges
New England Journal of Medicine, Volume 395, Issue 15, Page 1505-1518, October 15, 2026.
Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL New England Journal of Medicine, Volume 395, Issue 15, Page 1483-1494, October 15, 2026.
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis New England Journal of Medicine, Volume 395, Issue 15, Page 1495-1504, October 15, 2026.
Obinutuzumab in Active Systemic Lupus Erythematosus New England Journal of Medicine, Volume 395, Issue 15, Page 1562-1562, October 15, 2026.
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity New England Journal of Medicine, Volume 395, Issue 15, Page 1562-1564, October 15, 2026.
Once-Weekly Mosnodenvir as Dengue Prophylaxis in a Human Infection Model New England Journal of Medicine, Volume 395, Issue 15, Page 1553-1555, October 15, 2026.
Integration-Associated Paraspinal Neoplasm after AAV Gene Therapy New England Journal of Medicine, Volume 395, Issue 15, Page 1555-1558, October 15, 2026.
Adapting to Genomic Medicine New England Journal of Medicine, Volume 395, Issue 15, Page 1541-1542, October 15, 2026.
Flushing in Carcinoid Syndrome New England Journal of Medicine, Volume 395, Issue 15, October 15, 2026.
Case 29-2026: A 39-Year-Old Man with Abdominal Pain, Foot Drop, and a Spinal Mass New England Journal of Medicine, Volume 395, Issue 15, Page 1530-1539, October 15, 2026.
Firearm-Related Discussions as an Age-Friendly Intervention New England Journal of Medicine, Volume 395, Issue 15, Page 1461-1463, October 15, 2026.
Not Available in Your Country New England Journal of Medicine, Volume 395, Issue 15, Page 1468-1469, October 15, 2026.
Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty New England Journal of Medicine, Ahead of Print.
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy New England Journal of Medicine, Ahead of Print.
Eplontersen for Transthyretin Amyloid Cardiomyopathy New England Journal of Medicine, Ahead of Print.
Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension New England Journal of Medicine, Ahead of Print.
Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain New England Journal of Medicine, Ahead of Print.
Tozorakimab to Prevent COPD Exacerbations New England Journal of Medicine, Ahead of Print.
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy New England Journal of Medicine, Ahead of Print.
Short or Long Antibiotic Regimens in Orthopedics New England Journal of Medicine, Ahead of Print.
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes New England Journal of Medicine, Ahead of Print.
Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes New England Journal of Medicine, Ahead of Print.
Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury New England Journal of Medicine, Ahead of Print.
The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome New England Journal of Medicine, Ahead of Print.
Spinal Tuberculosis New England Journal of Medicine, Ahead of Print.
Why Shared-Savings ACOs Have Failed to Deliver for Primary Care New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
|
Highlights of ASCO 2026
Volume 31, Issue 11, November 2026, oyag354 REVERCE II: a phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer Volume 31, Issue 11, November 2026, oyag307 Comparative safety of concurrent adjuvant trastuzumab emtansine vs trastuzumab with radiotherapy in HER2-positive early breast cancer Volume 31, Issue 11, November 2026, oyag372 Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers Volume 31, Issue 11, November 2026, oyag373 Current landscape of RAS-targeted therapy for pancreatic cancer Volume 31, Issue 11, November 2026, oyag379 Genomic and transcriptomic correlates of deep prostate–specific antigen response in patients with metastatic androgen pathway modulation–sensitive prostate cancer Volume 31, Issue 11, November 2026, oyag368 Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer Volume 31, Issue 11, November 2026, oyag375 Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework Volume 31, Issue 11, November 2026, oyag371 Target trial emulation studies in oncology: a comprehensive analysis Volume 31, Issue 11, November 2026, oyag258 Immune checkpoint inhibitors in resectable and locoregionally advanced HNSCC: past lessons, present evidence, and future directions Volume 31, Issue 11, November 2026, oyag366 Immune checkpoint inhibitors induced autoimmune hemolytic anemia in patients with malignant cancer Volume 31, Issue 11, November 2026, oyag395 Incidence of and risk factors for immune checkpoint inhibitor–related pneumonitis in thoracic malignancies: a prospective multicenter study Volume 31, Issue 11, November 2026, oyag377 Chemotherapy backbone and outcomes of immune checkpoint inhibitor combinations across solid tumors: a pan-tumor network meta-analysis Volume 31, Issue 11, November 2026, oyag365 Acrokeratosis paraneoplastica (Bazex syndrome): a systematic review and quantitative analysis of 106 cases Volume 31, Issue 11, November 2026, oyag376 Precision oncology at speed: workflow design determines clinical utility in rapid molecular testing for lung cancer Volume 31, Issue 11, November 2026, oyag388 Prognostic disclosure, end-of-life communication, and social support associated with distinct dyadic death-preparedness states among cancer dyads Volume 31, Issue 11, November 2026, oyag381 Cannabis assessment in oncology patients—evaluation survey: understanding usage patterns in a rural radiation cohort in Kentucky Volume 31, Issue 11, November 2026, oyag370 Reconsidering the incremental prognostic value of variant allele frequency-based stratification beyond European LeukemiaNet 2022 in acute myeloid leukemia Volume 31, Issue 11, November 2026, oyag406 Correction: Linking early and late endpoints in adjuvant immunotherapy trials: an evaluation of multiple clinical outcomes Volume 31, Issue 11, November 2026, oyag399 |
A Penny for Your Thoughts October 2026: 69(10):2399-2401 Ventral Mesh Rectopexy and Rectal Cancer: An Underrecognized Concern October 2026: 69(10):2402-2403 Artificial Intelligence for Colorectal Surgeons—Part II: Research Applications, Challenges in Adoption, and Practical Resources October 2026: 69(10):2404-2412 What Every Colorectal Surgeon Should Know About Private Equity in Ambulatory Practices: Structure, Practice Models, and Implications for Physicians October 2026: 69(10):2413-2417 Compliance With the American Society of Colon and Rectal Surgeons Preoperative Checklist in Rectal Cancer Care in Ghana: Gaps and Opportunities for Improvement—A Cross-Sectional Study October 2026: 69(10):2418-2424 Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2425-2428 Expert Commentary on Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2429-2430 The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Left-Sided Colonic Diverticulitis October 2026: 69(10):2431-2450 Lymph Node Harvest and Prognosis in Stage II and III Rectal Cancer in the Era of Total Neoadjuvant Therapy October 2026: 69(10):2451-2461 Outcomes and Molecular Correlates of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases October 2026: 69(10):2462-2472 Three-Year Follow-up of the Randomized Trial Comparing Open Versus Laparoscopic Surgery for Primary Tumor Resection in Patients With Noncurable Stage IV Colon Cancer (JCOG1107) October 2026: 69(10):2473-2483 Five-Year Follow-up of the Double-Blinded Randomized Controlled Trial Comparing Laser Hemorrhoidoplasty With Sutured Mucopexy and Excisional Hemorrhoidectomy October 2026: 69(10):2484-2491 Patterns and Outcomes of Elective Versus Nonelective Rectal Prolapse Repair: An American College of Surgeons National Quality Surgical Improvement Program Analysis October 2026: 69(10):2492-2499 Short- and Long-term Outcomes of 3-Row Vs 2-Row Circular Staplers for Low Colorectal Anastomosis After Total Mesorectal Excision: A Single-Center, Randomized, Single-Blind, Phase III Trial (THREESTAPLER Study) October 2026: 69(10):2500-2510 Clinical and Physiological Characterization of Neurogenic Bowel Dysfunction in Motor-Incomplete Spinal Cord Injury October 2026: 69(10):2511-2520 Computer Vision Approach to Triaging Patient-Submitted Photos of Intestinal Ostomies October 2026: 69(10):2521-2530 Selected Abstracts October 2026: 69(10):2531-2534 Single Incision Plus One Robot-Assisted Surgery for Right-Sided Colon Cancer October 2026: 69(10):2535-2535 Video Demonstration of Single-Port Robotic Transanal Total Mesorectal Excision Using Newly Developed Surgical Robot System October 2026: 69(10):2536-2537 Mastering the Planes: Laparoscopic Left Hemicolectomy With Complete Mesocolic Excision October 2026: 69(10):2538-2539 |
|
|
| |||
|
Verifying the Seen and Unseen by AI in Cancer Imaging
Artificial intelligence (AI) can be used in medical imaging and diagnostics to enhance physician capabilities, but also to identify features that humans are not able to see. In research settings, AI has already demonstrated that ability to identify biomarkers from routine medical images and guide... AI-Extracted Chart Data for Expanding Surgical Oncology Learnings Large language models (LLMs) are capable of extracting structured data directly from electronic medical records, expanding data sets available for research, training, and developing artificial intelligence (AI) models. Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families, Study Finds New research published by Rodwin et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that families of children receiving treatment for B-cell acute lymphoblastic leukemia (ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a... Friday, October 16, 2026 11:04 AM Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). Thursday, October 15, 2026 4:39 PM ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ... FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). Wednesday, October 14, 2026 12:45 PM Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD... Amyloidosis: Novel Treatments Could Improve Poor Outcomes Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual... Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer A prospective study found that sentinel lymph node biopsy may be an accurate method of axillary staging in selected patients with locally advanced breast cancer who achieve a clinical nodal response to neoadjuvant chemotherapy—potentially allowing some patients to avoid axillary lymph node... Study Supports Universal Germline Genetic Testing Regardless of Age at Cancer Diagnosis Universal germline genetic testing after an individual receives a cancer diagnosis may help to uncover hereditary cancer risks in the patient's family, according to findings published in Cancer Discovery. Thursday, October 15, 2026 10:00 AM ASCO and WHO Formalize Partnership Cancer is one of the leading causes of morbidity and mortality worldwide, affecting 92% of families around the world, according to the latest estimates from the World Health Organization (WHO) Global status report on cancer 2026. The highest health, social, and economic burdens occur in low- and... Thursday, October 15, 2026 10:20 AM FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA... Friday, October 9, 2026 10:38 AM Short-Course SBRT Better Preserves Physical Function Before Pancreatic Cancer Surgery Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with 5 treatments of stereotactic body radiation therapy (SBRT) than with 28 treatments of conventional radiation therapy given with chemotherapy, according to findings of a randomized... Tuesday, September 29, 2026 10:51 AM Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma Nearly half of patients with resected high-risk melanoma treated with adjuvant anti–PD-1 therapy developed chronic immune-related adverse events, and more than one-third still had ongoing toxicity after a median follow-up of more than 5 years. Roma A. Kankaria, MD, and colleagues reported the... Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ... Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project Pain is an incredibly challenging symptom that affects over 40% of patients with cancer in active treatment1 and up to two in three patients with advanced cancer.2 Analgesic pain medications including opioids have been the predominant pain management strategy; however, their use is limited by... Facilitated Cascade Genetic Testing Improves Uptake Among Relatives of BRCA1/2 Variant Carriers According to findings from a randomized controlled trial reported by Wilke et al in the Journal of Clinical Oncology, a clinician-facilitated approach to cascade genetic testing significantly increased genetic testing uptake among first-degree relatives of individuals with BRCA1 or BRCA2 pathogenic ... Automated vs Handheld Ultrasound for Breast Cancer Screening A new study by Rauscher et al in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, whereas ABUS had a lower false-positive rate. These data demonstrate... Wednesday, October 14, 2026 10:00 AM Remote Exercise Program Reduces Cancer-Related Fatigue, Improves Quality of Life for Patients Undergoing Immunotherapy A supervised remote exercise program improved the quality of life of patients with cancer undergoing immunotherapy, primarily by reducing cancer fatigue, according to findings from a secondary analysis of a phase II trial that will be presented at the 2026 ASCO Quality Care Symposium (Abstract... Tuesday, October 13, 2026 12:00 PM ASCO Remembers Dr. Rachna T. Shroff, Expert in Gastrointestinal Cancers and Dedicated ASCO Volunteer ASCO joins the oncology community in mourning the death of Rachna T. Shroff, MD, MS, FASCO, a renowned expert specializing in gastrointestinal (GI) cancers and a dedicated ASCO volunteer. Dr. Shroff passed away following a battle with an aggressive cancer. Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC Daraxonrasib produced responses in more than 30% of patients with previously treated advanced RAS-mutant non–small cell lung cancer (NSCLC), with activity observed across multiple RAS mutations in a phase I/II study. Results from Kathryn C. Arbour, MD, David S. Hong, MD, and colleagues were... Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC Relapsed small cell lung cancer (SCLC) remains a major therapeutic challenge, with limited treatment options and poor outcomes after disease progression on platinum-based chemotherapy and immunotherapy. At the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on... Wednesday, September 16, 2026 12:04 PM Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC An 8-year update of the phase III ADAURA trial showed that adjuvant osimertinib continued to demonstrate an overall survival benefit over placebo in patients with resected EGFR-mutated non–small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study ... Wednesday, September 16, 2026 12:00 PM Financial Navigation Support May Help Reduce Financial Toxicity for Some People With Advanced Cancer Results from the randomized nationwide CREDIT trial showed that a financial navigation support program does not broadly reduce financial hardship for people being treated for advanced cancer. However, it can help a subgroup of people: those with existing financial and social resources that make... Tuesday, October 13, 2026 11:43 AM Anitocabtagene Autoleucel Shows High Response Rate in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Anitocabtagene autoleucel (anito-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, produced responses in all treated patients in a phase I study of heavily pretreated relapsed or refractory multiple myeloma, with 79% achieving a... Study Identifies Insurance and Cost Barriers to Oral Therapies for Blood Cancers A nationwide study of patients with blood cancers found that most prescriptions for specialty oral anticancer medications were initially rejected by insurers, and many patients did not fill their prescriptions even after receiving approval. The findings, reported by Doshi et al in the Journal of... |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval
The FDA recently approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Critics call the second clause non-evidence based. However, this imprecision enables access: trials generally enrol only patients with good performance status, which does not reflect the realities for most patients with metastatic pancreatic adenocarcinoma who never reach second-line therapy because their clinical condition deteriorates first. Real-world evidence should resolve any remaining uncertainty. Tue, 13 Oct 2026 00:00:00 -0700 A modular framework for antibody–drug conjugate biomarkers Antibody–drug conjugates (ADCs) have transformed the management of various advanced-stage solid cancers. Nonetheless, and despite considerable development efforts, many of these agents lack reliable biomarkers of clinical benefit and/or are reliant on traditional methods of biomarker assessment, with biomarkers of resistance and/or toxicity largely overlooked. In this Review, the authors outline a modular ADC biomarker development strategy that considers the various components of these agents and discuss how biomarkers developed using this strategy might better inform patient selection, therapeutic sequencing, the development of rational combinations, dose optimization and regulatory strategy. Fri, 09 Oct 2026 00:00:00 -0700 Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma Thu, 08 Oct 2026 00:00:00 -0700 Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum The iterative development of several highly effective treatments for HER2-positive breast cancer has transformed patient outcomes, but the now-crowded therapeutic landscape raises questions regarding the optimal approach for each patient. In this Review, the authors outline considerations for right-sizing therapy across the disease continuum, and discuss biomarkers that might facilitate this more individualized approach to treatment. Thu, 08 Oct 2026 00:00:00 -0700 Exercise therapy in cancer prevention and treatment Exercise is widely endorsed as a supportive-care adjunct to mitigate adverse effects of cancer treatment, with data also suggesting potential therapeutic and preventive roles. In this Review, the authors discuss the current evidence from epidemiological studies and clinical trials for exercise as a factor modulating primary cancer risk and disease outcomes after diagnosis, and describe a translational framework for continued development of exercise therapy and a path towards precision exercise oncology. Wed, 07 Oct 2026 00:00:00 -0700 Exploring the immunological effects of antibody–drug conjugates Antibody–drug conjugates (ADCs) have reshaped the therapeutic landscape of many advanced-stage cancers. This clinical activity probably reflects mechanisms beyond targeted cytotoxicity, with emerging evidence suggesting an immune-mediated component. At the same time, regimens combining ADCs with immune checkpoint inhibitors (ICIs) are emerging as a highly effective treatment strategy in various malignancies. In this Review, the authors discuss the immunological mechanisms of action of ADCs, their clinical activity in combination with ICIs, as well as the potential of future agents and regimens to further improve outcomes. Tue, 06 Oct 2026 00:00:00 -0700 Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL Thu, 01 Oct 2026 00:00:00 -0700 Optimizing the delivery of radiotherapy with artificial intelligence Radiation oncology involves complex, data-intensive clinical workflows, which makes this medical specialty an ideal setting for leveraging the unique capabilities of artificial intelligence (AI). The authors of this Review present examples of successful AI applications in radiation oncology, present the current challenges for successful clinical implementation of these applications and discuss broader implications, such as the need to ensure safe and optimal use of AI in order to improve patient outcomes. Thu, 24 Sep 2026 00:00:00 -0700 |
|
|
| |||
|
Prognostic significance of DNA damage response-related markers in esophageal squamous cell carcinoma using machine learning approaches
Vol 17, No 4 (August 31, 2026): The association between coffee consumption and esophageal cancer risk: a systematic review and meta-analysis of current observational evidence Vol 17, No 4 (August 31, 2026): FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2 Vol 17, No 4 (August 31, 2026): Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study Vol 17, No 4 (August 31, 2026): Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prediction-model development and temporal validation for six-month cancer-specific mortality in de novo metastatic gastroesophageal junction adenocarcinoma: a SEER-based study Vol 17, No 4 (August 31, 2026): Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study Vol 17, No 4 (August 31, 2026): Nodal status and advanced clinical stage as determinants of response and survival after induction chemoradiotherapy in esophageal and gastroesophageal junction cancer: a single-centre retrospective cohort study Vol 17, No 4 (August 31, 2026): Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma Vol 17, No 4 (August 31, 2026): Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway Vol 17, No 4 (August 31, 2026): The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Cuproplasia-associated LOXL2 cooperates with Helicobacter pylori infection to promote gastric cancer progression via the FAK/Src signaling axis Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study Vol 17, No 4 (August 31, 2026): Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM Vol 17, No 4 (August 31, 2026): Helicobacter pylori-induced cystathionine-γ-lyase drives redox imbalance and metabolic remodeling in gastric cancer Vol 17, No 4 (August 31, 2026): Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study Vol 17, No 4 (August 31, 2026): Increased expression of Ribonucleic acid export 1 (RAE1) gene promotes gastric carcinogenesis and is associated with Hippo signaling pathway Vol 17, No 4 (August 31, 2026): Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer Vol 17, No 4 (August 31, 2026): Distinct metastatic patterns and survival outcomes in intestinal- versus diffuse-type gastric cancer: a SEER-based propensity score-matched analysis Vol 17, No 4 (August 31, 2026): Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression Vol 17, No 4 (August 31, 2026): A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators Vol 17, No 4 (August 31, 2026): Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study Vol 17, No 4 (August 31, 2026): Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study Vol 17, No 4 (August 31, 2026): Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression Vol 17, No 4 (August 31, 2026): Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis Vol 17, No 4 (August 31, 2026): Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer Vol 17, No 4 (August 31, 2026): Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study Vol 17, No 4 (August 31, 2026): Association between metabolic dysfunction-associated steatotic liver disease and risk of early-onset advanced colorectal neoplasia: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration Vol 17, No 4 (August 31, 2026): Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study Vol 17, No 4 (August 31, 2026): Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study Vol 17, No 4 (August 31, 2026): A study on screening of postoperative chemotherapy beneficial populations in stage II colorectal cancer based on diffusion weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography Vol 17, No 4 (August 31, 2026): Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer Vol 17, No 4 (August 31, 2026): Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Vol 17, No 4 (August 31, 2026): Prognostic impact of mucinous adenocarcinoma after curative surgery for stage I–III colorectal cancer: a large population-based cohort study Vol 17, No 4 (August 31, 2026): Comparative analysis of outcomes and sociodemographic factors in early- and late-onset colorectal cancer hospitalizations Vol 17, No 4 (August 31, 2026): Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis Vol 17, No 4 (August 31, 2026): Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior Vol 17, No 4 (August 31, 2026): Prediction of histological response by PET-CT after 2 weeks of neoadjuvant chemo-radiotherapy for rectal cancer: a prospective clinical trial Vol 17, No 4 (August 31, 2026): Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy Vol 17, No 4 (August 31, 2026): Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection Vol 17, No 4 (August 31, 2026): Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial Vol 17, No 4 (August 31, 2026): Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries Vol 17, No 4 (August 31, 2026): Development and validation of a novel nomogram for predicting long-term survival in gallbladder cancer: a large population-based study using the SEER database Vol 17, No 4 (August 31, 2026): Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection Vol 17, No 4 (August 31, 2026): Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Immunological characteristics of calmodulin-related genes in hepatocellular carcinoma and their potential for prognostic prediction and diagnostic applications Vol 17, No 4 (August 31, 2026): Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis Vol 17, No 4 (August 31, 2026): Relationships among slow diffusion coefficient and diffusion-derived ‘vessel density’ signal features, Gadoxetate delayed enhancement, tumor size, tumor grading, and patient survival: an exploratory study of mass-forming intrahepatic cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Construction of molecular signatures based on the co-expression network of NECSO-related gene TRPM4 and its prognostic value in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study Vol 17, No 4 (August 31, 2026): A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study Vol 17, No 4 (August 31, 2026): SLC25A45 as a prognostic biomarker promotes malignant progression via mutant p53 in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A novel glutamine metabolism-based classification system for characterizing the heterogeneity of hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A CFH- and SPINT2-based prognostic signature for cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990–2023: an analysis based on the Global Burden of Disease Study 2023 Vol 17, No 4 (August 31, 2026): Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram based on three-dimensional quantitative parameters from dual-layer detector spectral computed tomography for predicting treatment response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma Vol 17, No 4 (August 31, 2026): Chronic psychological stress and gastric cancer: bidirectional associations, biological mechanisms, and clinical implications—a narrative review Vol 17, No 4 (August 31, 2026): MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies—a narrative review Vol 17, No 4 (August 31, 2026): Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review Vol 17, No 4 (August 31, 2026): From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer Vol 17, No 4 (August 31, 2026): Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial Vol 17, No 4 (August 31, 2026): Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features Vol 17, No 4 (August 31, 2026): Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts Vol 17, No 4 (August 31, 2026): Non-operative management of rectal adenocarcinoma in a safety-net system: a decade of real-world outcomes outside watch-and-wait eligibility Vol 17, No 4 (August 31, 2026): Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prognostic role of resting heart rate in patients with colorectal cancer Vol 17, No 4 (August 31, 2026): DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation Vol 17, No 4 (August 31, 2026): Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma? Vol 17, No 4 (August 31, 2026): Optimizing hepatocellular carcinoma screening in the era of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease: time to lower the alpha-fetoprotein threshold Vol 17, No 4 (August 31, 2026): Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting Vol 17, No 4 (August 31, 2026): Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash Vol 17, No 4 (August 31, 2026): Endoscopic ultrasonography ablation for small pancreatic neuroendocrine tumors Vol 17, No 4 (August 31, 2026): Extending the utility of anti-EGFR therapy in metastatic colorectal cancer Vol 17, No 4 (August 31, 2026): Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity? Vol 17, No 4 (August 31, 2026): Ferroptosis in gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 4 (August 31, 2026): |
|
||
|
| |||
|
Patient-Centered Prescription Opioid Tapering Methods
Annals of Internal Medicine, Volume 179, Issue 9, Page 1221-1231, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy Annals of Internal Medicine, Volume 179, Issue 9, Page 1232-1243, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy Annals of Internal Medicine, Volume 179, Issue 9, Page 1244-1253, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis Annals of Internal Medicine, Volume 179, Issue 9, Page 1254-1261, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis Annals of Internal Medicine, Volume 179, Issue 9, Page 1262-1270, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Surgery Versus Watchful Waiting for First Metatarsophalangeal Joint Osteoarthritis Annals of Internal Medicine, Volume 179, Issue 9, Page 1271-1279, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Strengthening the Reporting of Observational Studies in Epidemiology Enhanced Prevalence and Incidence Criteria (STROBE EPIC): An Extension of the STROBE Statement Annals of Internal Medicine, Volume 179, Issue 9, Page 1280-1289, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Adult Overweight and Obesity Management: Updates From the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines Annals of Internal Medicine, Volume 179, Issue 9, Page 1296-1311, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Modernizing the Regulatory Framework for Dietary Supplements: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 9, Page 1290-1292, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Public Policy Approaches to Addressing Adult Obesity: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 9, Page 1293-1295, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Dialysis and the Politics of Self-care: The Enduring Effects of Barriers Imposed on Home Dialysis Annals of Internal Medicine, Volume 179, Issue 9, Page 1312-1318, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop Annals of Internal Medicine, Volume 179, Issue 9, Page 1319-1327, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1–Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop Annals of Internal Medicine, Volume 179, Issue 9, Page 1328-1337, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Rethinking the Global Transition to LED Lighting: Balancing Energy Efficiency With Human Physiology Annals of Internal Medicine, Volume 179, Issue 9, Page 1338-1340, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 When the Physician Becomes a Candidate Annals of Internal Medicine, Volume 179, Issue 9, Page 1341-1342, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Early Access to GLP-1 Receptor Agonists for Weight Management in Medicare: The GLP-1 Bridge Demonstration Annals of Internal Medicine, Volume 179, Issue 9, Page 1343-1345, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Assessing Front-of-Package Labels: The U.S. Food and Drug Administration’s Proposed Rule in Context Annals of Internal Medicine, Volume 179, Issue 9, Page 1346-1347, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Why Patients Ask the Chatbot First Annals of Internal Medicine, Volume 179, Issue 9, Page 1348-1349, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Securing Patient-Centered Decision Making With Adults With Intellectual and Developmental Disabilities Annals of Internal Medicine, Volume 179, Issue 9, Page 1350-1351, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Beyond “Provider”: Recommendations to Turn Consensus Into Action Annals of Internal Medicine, Volume 179, Issue 9, Page 1352-1353, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Patient-Centered Opioid Tapering: What Is It, and Does It Work? Annals of Internal Medicine, Volume 179, Issue 9, Page 1354-1355, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 A Thousand Letters Annals of Internal Medicine, Volume 179, Issue 9, Page 1356-1357, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 The Cardinal in the Bamboo Annals of Internal Medicine, Volume 179, Issue 9, Page 1358-1359, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 How to Be a Patient Annals of Internal Medicine, Volume 179, Issue 9, Page 1360-1360, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 A Cross-Sectional Assessment of Differences in the U.S. Health Care Workforce by Urbanicity, 2019 to 2023 Annals of Internal Medicine, Volume 179, Issue 9, Page 1361-1363, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 Outpatient Antibiotic Prescribing for Uncomplicated Diverticulitis in Veterans Affairs Facilities: A Retrospective Cohort Study Annals of Internal Medicine, Volume 179, Issue 9, Page 1363-1365, September 2026. <br/> Tue, 07 Jul 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel.
Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.
Biogen’s big lupus bet gets boost from new durability data for skin disease All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study. Data from two Phase 3 studies of systemic lupus are expected by the end of the year.
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
US government launches AI-driven programs to overhaul clinical trials Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection.
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.
Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 VeraMorph Completes Positive Pre-IND Meeting on Oral Fulvestrant Product, Receives NIH SBIR Phase II Grant, and Names New CEO Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026 Eclipse Life Sciences Announces Positive Topline Results from Phase 2 BETTIS-1 Study Evaluating EC-104 for Diabetic Macular Edema (DME) Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase 2 Combination Study in First-Line Patients with Advanced Colorectal Cancer PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma |
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4 readout for Nereus in GLP-1-induced vomiting.
BMS’ Phase 3 win for lung drug clouded by high-dose miss A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.
RevMed’s Rasonque gets a subtype data asterisk, but analysts remain bullish Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner.
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold After one patient death prompted an FDA hold this spring, Newron Pharmaceuticals has now shared that a total of four fatalities have been recorded among participants receiving its schizophrenia candidate. A fifth death was recorded among those taking the placebo.
Cerevance Parkinson’s drug shortens ‘off time’ in Ph. 3, paving path to FDA The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.
ArriVent sheds nearly half of value on late-stage lung cancer miss ArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine kinase inhibitor in a different type of lung cancer and to the biotech’s antibody-drug conjugate pipeline.
AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3 AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche’s Polivy.
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 Pelage Pharmaceuticals Announces First Patient Dosed in Phase 2/3 AWAKEN Trial of PP405 for Androgenetic Alopecia, the Most Common Form of Hair Loss AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn’s Disease āshibio Presents Preliminary Efficacy Data for Andecaliximab Demonstrating an 86.2% Reduction in New Flare-Up Rate in Patients with FOP GC Biopharma to Present Expanded IVIG Aggregation Analysis and Additional Phase 3 ALYGLO® Safety Analysis at IgNS 2026 Legacy Healthcare’s CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older Applied Biologics Announces First Patient Treated in Phase 3 BIOxHEAL™ Clinical Trial Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn’s disease patient subgroups |
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop
Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel.
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4 readout for Nereus in GLP-1-induced vomiting.
The decisions behind scientific progress In this episode of Denatured, presented by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we explore how biopharma’s real bottleneck isn’t too little data—it’s too little confidence in the decisions that drive development, manufacturing and commercialization.
Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.
BMS’ Phase 3 win for lung drug clouded by high-dose miss A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.
RevMed’s Rasonque gets a subtype data asterisk, but analysts remain bullish Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner.
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.
Palleon Pharmaceuticals Announces Oral Presentation of Interim Phase 2 trial data for HLX79/E-602 in Membranous Nephropathy at the 2026 American College of Rheumatology (ACR) Convergence Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 VeraMorph Completes Positive Pre-IND Meeting on Oral Fulvestrant Product, Receives NIH SBIR Phase II Grant, and Names New CEO Alimentiv and International Bowel Ultrasound Group Expand Partnership to Include Ultrasound Training for Clinical Trials DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma Paradigm Clinical Research Expands into Nevada with New Las Vegas Clinical Trial Site Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference |
|
|
| |||
|
FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors to include patients with high-grade papillary-only tumors.
Wed, 14 Oct 2026 00:00:02 -0700
FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
Thu, 08 Oct 2026 00:00:02 -0700
FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
Wed, 07 Oct 2026 00:00:02 -0700
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
Fri, 02 Oct 2026 00:00:02 -0700
FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Thu, 24 Sep 2026 00:00:02 -0700
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
Wed, 23 Sep 2026 00:00:02 -0700
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
Fri, 18 Sep 2026 00:00:02 -0700
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Wed, 09 Sep 2026 00:00:02 -0700
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Fri, 04 Sep 2026 00:00:02 -0700
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Wed, 26 Aug 2026 00:00:02 -0700
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma Tue, 25 Aug 2026 00:00:02 -0700
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 13 Aug 2026 00:00:02 -0700
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Thu, 06 Aug 2026 00:00:02 -0700
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
Fri, 31 Jul 2026 00:00:02 -0700
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Wed, 22 Jul 2026 00:00:02 -0700
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Tue, 14 Jul 2026 00:00:02 -0700
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Tue, 14 Jul 2026 00:00:02 -0700
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:00:02 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:00:02 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:02 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:02 -0700
|
Self-medication of attention-deficit/hyperactivity disorder symptoms with psychoactive substances in adults: a scoping review of how symptom-relief motives are framed and operationalised across substances.
Front Psychiatry. 2026 Sep 30;17:1966206. doi: 10.3389/fpsyt.2026.1966206. eCollection 2026. Adamou M, Petrou C Medical cannabis for the treatment of insomnia. Cochrane Database Syst Rev. 2026 Oct 13;10(10):CD016216. doi: 10.1002/14651858.CD016216.pub2. Varela LB, Miño Zambrano JE, Maura Goncalves Costa B, Santos Marques da Silva G, Escobar Liquitay CM, Díaz Menai S, Meza N, Garegnani LI Parasites in grizzly bears from the central Canadian Arctic. J Wildl Dis. 1999 Jul;35(3):618-21. doi: 10.7589/0090-3558-35.3.618. Gau RJ, Kutz S, Elkin BT Microalgae as tools for bio-circular-green economy: Zero-waste approaches for sustainable production and biorefineries of microalgal biomass. Bioresour Technol. 2023 Nov;387:129620. doi: 10.1016/j.biortech.2023.129620. Epub 2023 Aug 5. Cheirsilp B, Maneechote W, Srinuanpan S, Angelidaki I International Society of Sports Nutrition position stand: diets for body weight reduction. J Int Soc Sports Nutr. 2026 Dec 30;23(1):2740266. doi: 10.1080/15502783.2026.2740266. Epub 2026 Oct 13. Aragon AA, Campbell BI, Schoenfeld BJ, Stout JR, Kalman D, Arciero PJ, Arent SM, Kreider RB, Taylor LW, Bannock L, Wildman REC, Kerksick CM, Antonio J Attention deficit hyperactivity disorder: transition to psychotic disorders. Mol Psychiatry. 2026 Oct 14. doi: 10.1038/s41380-026-03926-4. Thapar A, Dennison CA, Kandeğer A, Owen MJ Development of the Movement Pattern Observation Tool (MPOT)-An Observational Tool to Measure Limb Movements during Elementary School Recess. Int J Environ Res Public Health. 2023 Apr 20;20(8):5589. doi: 10.3390/ijerph20085589. Webb GK, Rhea DJ Prenatal Sonographic Features of Ring Chromosome 15: A Case Report and Literature Review. Diagnostics (Basel). 2022 Apr 1;12(4):885. doi: 10.3390/diagnostics12040885. Traisrisilp K, Yanase Y, Phirom K, Tongsong T Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2026 Oct 14. doi: 10.1056/NEJMoa2608397. Gaudry S, Boubaya M, Louis G, Chaïbi K, de Montmollin E, Bohé J, Desgrouas M, Devautour C, Joseph A, Mégarbane B, Camus C, Bailly P, Lambour A, Arrestier R, Jaber S, Robine A, Chudeau N, Chevrel G, La Combe B, Nicolas J, Argaud L, Bureau C, Kimmoun A, Zucman N, Ricard JD, Thiery G, Faguer S, Jozwiak M, Ferrand N, Chousterman B, Marzouk M, Cadiet J, Combes A, Mari A, Contou D, Amathieu R, Da Silva D, Gandonnière CS, Rodie-Talbere PA, Durand-Zaleski I, Rossignol P, Quenot JP, Biard L, Bloch C, Dreyfuss D; ICRAKI Trial Group Beyond libido: the multifaceted role of testosterone in women. Sex Med Rev. 2026 Sep 30;14(4):qeag072. doi: 10.1093/sxmrev/qeag072. Hernandez BS, Covarrubias A, Perez-Grego PG, Coady PJ, Walia A, Casperson K, Newson L, Lyon G, Khera M Adult Attention Deficit-Hyperactivity Disorder. N Engl J Med. 2026 Oct 15;395(15):1519-1528. doi: 10.1056/NEJMcp2516040. Buitelaar JK, Newcorn JH Interference by reactions of kynurenine metabolism in the estimation of tryptophan pyrrolase in rat-liver homogenate. Biochim Biophys Acta. 1963 Mar 12;67:513-6. doi: 10.1016/0006-3002(63)91859-6. JAGO MV, NELSON JF, ROSE S Intraoperative Dobutamine Plus Norepinephrine to Prevent Postoperative Acute Kidney Injury in Septic Shock: A Randomized Clinical Trial. JAMA. 2026 Oct 14:e2621322. doi: 10.1001/jama.2026.21322. Chinese Perioperative Septic Shock Investigators for the Chinese Peri-Operative Organ Protection Group; Chu L, Xie G, Shi R, Ye H, Wu S, Hua Y, Wang B, Tang M, Xu Z, Wang Q, Cui P, Ye J, Hong Y, Wang J, Xu G, Li Q, Wang C, Zheng F, Xia Z, Song W, Wang M, Chen L, Lu X, Liu X, Zheng Q, Tang J, Yan Z, Lang B, Yan Q, Liu W, Luo J, Wang K, Lu Y, Huang C, Wang J, Zhang H, Li F, Lu K, Yi B, Gu J, Wu J, Duan G, Li C, Luo F, Wang H, Zhang J, Han Y, Tan D, Wen J, Wan H, Hu G, Yu T, Wang H, Mei W, Liu Z, Yu S, Guan Y, Wang X, Ma B, Yang Y, Wang H, Wu X, Chen Y, Lai Z, Han X, Ji F, Yang S, Wu Y, Li R, Xu P, Yang J, Nian C, Yu Y, Wang H, An X, Cheng B, Li H, Song S, Ma D, Islam N, Fang X Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. N Engl J Med. 2026 Oct 15;395(15):1483-1494. doi: 10.1056/NEJMoa2606208. Chiaretti S, Piciocchi A, Skert C, Leoncin M, Borlenghi E, Cattaneo C, Di Trani M, Elia L, Almici G, Cardinali D, Kaiser F, Lussana F, Fiumara PF, Maugeri C, Alati C, Martino M, Ansuinelli M, Lucco Navei G, Mattei D, Soddu S, Messina M, Marino MR, Mancini V, Chiusolo P, Scappini B, Martelli MP, Salutari P, Cerrano M, Serio B, Cucca A, Luppi M, Pochintesta L, Pasciolla C, Romani C, Mosna F, Bonifacio M, Tanasi I, Fracchiolla NS, Bocchia M, Imbergamo S, Califano C, Nunziata GR, Annunziata M, Mulé A, Zappasodi P, Mastaglio S, Butera S, Della Porta MG, Porretto F, Lunghi M, De Bellis E, Todisco E, Basilico CM, Fazi P, Rambaldi A, Bassan R, Foà R; GIMEMA Investigators Lifestyle factors of people with exceptional longevity. J Am Geriatr Soc. 2011 Aug;59(8):1509-12. doi: 10.1111/j.1532-5415.2011.03498.x. Epub 2011 Aug 3. Rajpathak SN, Liu Y, Ben-David O, Reddy S, Atzmon G, Crandall J, Barzilai N Sirenomelia Sympus Dipus: Autopsy Case Report of a Second-Trimester Fetus With Multiple Congenital Anomalies. Cureus. 2026 Jun 2;18(6):e110114. doi: 10.7759/cureus.110114. eCollection 2026 Jun. Cantú Perches GA, Pulido Puente PP, Lugo Morán LA Cyclic GMP causes Ca2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. J Biol Chem. 1997 Feb 21;272(8):5063-8. doi: 10.1074/jbc.272.8.5063. Lee MR, Li L, Kitazawa T In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles. Nat Biotechnol. 2026 Oct 13. doi: 10.1038/s41587-026-03310-1. Chen Y, Monkovic J, Mughal H, Chen B, Thadhani E, McMullen P, Self A, Chen Y, Hu Y, Detmer S, Chen M, Lapteva A, Kamat R, Vernon A, Langer R, Anderson DG UEFA consensus guidelines on anterior cruciate ligament (ACL) injury in Women's football - part one: risk factors and prevention. Sci Med Footb. 2026 Oct 14:1-13. doi: 10.1080/24733938.2026.2747391. Okholm Kryger K, Arundale AJH, Bahtijarevic Z, Brogden C, Chaput M, Conner-Rilk S, Datson N, Ezzat A, Ferrer E, Ferrer-Roca V, Filbay S, Frank B, Geertsema C, Hägglund M, Kerkhoffs G, Le CY, Lewin G, Linde X, van der List JP, Mayhew L, McKay CD, Moen C, Myklebust G, Nilsson T, Van den Steen E, Whalan M, Yanguas J, Monthuley G, Verhagen E Fluid Therapy in Mechanically Ventilated Critically Ill Adult Patients. JAMA. 2026 Oct 14:e2621291. doi: 10.1001/jama.2026.21291. Blok SG, de Grooth HJ, Pisani L, Barbas C, Chew M, Dubin A, Hammond N, Kwizera A, Malbrain MLNG, Monnet X, Myatra SN, Rose L, Neto AS, Shi Z, Silversides J, Tripathy S, van Haren F, Dondorp A, Schultz MJ, van Regenmortel N, Paulus F, Tuinman PR; PRoFLUID Investigators |
||